COL.ACS

About this trial

Last updated 10 years ago

Study ID

COL.ACS

Status

Unknown status

Type

Interventional

Phase

Phase 4

Placebo

Yes

Accepting

Up to 80 Years

All

Not accepting

Healthy Volunteers

Trial Timing

Started 12 years ago

- There is evidence that inflammatory processes may play detrimental role during the acute phase of myocardial infarction - The hypothesis of this study is that colchicine, by its anti-inflammatory action, may lead to reduction in infarct size, when administered during the acute phase of myocardial infarction

Inclusion Criteria

- > 80 years old

- with active inflammatory diseases, infectious diseases or known malignancy

- under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents

- with known hypersensitivity-allergy to colchicine

- under chronic treatment with colchicine

- with severe renal failure (eGFR < 30 ml/min/1.73 m2)

- with hepatic failure (Child - Pugh class B or C)

- presenting with cardiac arrest

- presenting with ventricular fibrillation

- presenting with cardiogenic shock

- with stent thrombosis

- with angina within 48 hours before infarction

- with previous myocardial infarction

- with occlusion of the left main or left circumflex coronary artery or with evidence of coronary collaterals to the region at risk on initial coronary angiography (at the time of admission)

- with metallic implants (ferromagnetic material)

Colchicine in ST-elevation Myocardial Infarction